Lingrui Pharma released its first-quarter performance, with a net profit attributable to the parent company of 217 million yuan, a year-on-year increase of 13.89%

According to the Zhitong Finance APP, Lingrui Pharma released its first-quarter report for 2025. The company's first-quarter operating revenue was 1.021 billion yuan, a year-on-year increase of 12.29%; the net profit attributable to shareholders of the listed company was 217 million yuan, a year-on-year increase of 13.89%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 204 million yuan, a year-on-year increase of 12.38%; basic earnings per share were 0.383 yuan/share